Western Blot News and Research

RSS

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

New research deals with the development of RBD trimer as a potent target for SARS-CoV-2 subunit vaccines. This study revealed the development of a trimeric RBD subunit vaccine candidate that could induce strong humoral and cellular immune responses in nonhuman primates (NHPs), namely, rhesus macaques.

1 Apr 2021

New mRNA COVID-19 vaccine candidate shows promise in vivo

Researchers report that a new lipid nanoparticle mRNA coronavirus disease 2019 (COVID-19) vaccine candidate protected 70% of mice expressing the human angiotensin-converting enzyme 2 (ACE2), while all the non-vaccinated mice died.

31 Mar 2021

INTEGRA’s electronic pipettes eliminate user fatigue and improve pipetting productivity

CDI Labs – a biotechnology company based in Puerto Rico – is using INTEGRA’s VIAFLO and VOYAGER electronic pipettes to streamline workflows and improve accuracy for the development of next generation proteomics products.

From INTEGRA Biosciences 17 Mar 2021

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

A new study by researchers at Mahidol University in Bangkok, Thailand, reports a COVID-19 vaccine candidate called HexaPro in producing neutralizing antibodies against the SARS-CoV-2 spike protein in an animal model.

3 Mar 2021

Could measles virus vectors be used for a new COVID-19 vaccine?

A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.

18 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

Urinary shedding of spike protein in COVID-19 patients

A team of scientists from the United States has recently revealed that about 25% of people with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop renal complications and that the viral spike protein can be detected in the urine samples of these patients. The study is currently available on the medRxiv* preprint server.

1 Feb 2021

Researchers develop ‘next-generation vaccine platform’ against SARS-CoV-2

Researchers have designed a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG (Oligodeoxyribonucleotides) adjuvant.

29 Jan 2021

Hypoxia signaling pathway could lead to COVID-19 treatments

Researchers in Spain have demonstrated that studying the hypoxia signaling pathway could provide opportunities for treating coronavirus disease 2019 (COVID-19).

12 Jan 2021

Animal study suggests palmitoylation inhibitor reduces virulence of SARS-CoV-2

A new study preprint on the bioRxiv* server demonstrates the ability of a fatty acid synthase inhibitor to improve the survival of mice infected with murine hepatitis virus. In so doing, it adds to the sum of knowledge about the relationship of SARS-CoV-2 with cholesterol metabolism in the host cell.

24 Dec 2020

UCLA researchers identify gene that could help predict cervical cancer treatment response

UCLA researchers have identified a potential diagnostic marker that could help predict how likely someone with cervical cancer is to respond to the standard treatment of chemotherapy and radiation.

11 Dec 2020

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

In a study published in the journal Antiviral Research, researchers from Aarhus University, Denmark, report on their tests on different polyether ionophores to inhibit SARS-CoV-2 in vitro.

1 Dec 2020

Novel cannabis plant extracts could protect against COVID-19

Researchers in Canada have conducted a study suggesting that novel Cannabis sativa extracts may decrease levels of the host cell receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses to gain viral entry to target tissues.

26 Nov 2020

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers have developed a fluorescent reporter gene-bearing recombinant form of SARS-CoV-2, which is capable of replication.

23 Nov 2020

Optimizing SARS-COV-2 inactivation for COVID-19 research at lower biosafety levels

Researchers at Montana State University have validated and compared two methods for inactivating the causative agent of coronavirus disease 2019 (COVID-19) that would enable the virus to be studied at a lower biosafety level (BSL) than the one currently required.

18 Nov 2020

Affinity-Bead Assisted Mass Spectrometry for Proteomics

In this interview, Ghaith Hamza from AstraZeneca talks to News-Medical Life Sciences about the basic principles of Affinity-Bead Assisted Mass Spectrometry (Affi-BAMS) and how Affi-BAMS can help target specific proteins for proteomic applications.

From Bruker Daltonics 16 Nov 2020

Hypoxic exosomes promote stemness in EWS sarcoma, indicates study

The cover for issue 40 of Oncotarget features Figure 5, "miR-210 silences the proapoptosis member CASP8AP2," by Kling, et al. which reported that hypoxic Ewing's sarcoma cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by enhancing survival.

9 Oct 2020

Furin cleavage site of SARS-CoV-2 spike glycoprotein enhances viral replication in the lungs

In a new bioRxiv* preprint paper, researchers from the Imperial College London, King's College London, and the University of Bristol in the United Kingdom show that the furin cleavage site of SARS-CoV-2 spike glycoprotein represents a key determinant for transmission among humans, as it substantially facilitates replication in airway cells - opening the door for the development of novel therapeutics.

4 Oct 2020

India's whole-virion inactivated SARS-CoV-2 vaccine shows promise

Researchers in India have conducted a preclinical study demonstrating the safety and efficacy of a new candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

13 Sep 2020